Access-Capacity and Cost-Effectiveness for Future HIV Vaccines

2007 ◽  
Author(s):  
Daniel Barth-Jones ◽  
Raymond C.W. Hutubessy
Keyword(s):  
Cost Effectiveness ◽  
Hiv Vaccines

scholarly journals The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review

2017 ◽  
Vol 1 (1) ◽  
pp. 1-12 ◽  
Author(s):  
Blythe Adamson ◽  
Dobromir Dimitrov ◽  
Beth Devine ◽  
Ruanne Barnabas
Keyword(s):  
Systematic Review ◽  
Cost Effectiveness ◽  
Hiv Vaccines ◽  
Potential Cost

scholarly journals The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States

Vaccines ◽  
2017 ◽  
Vol 5 (2) ◽  
pp. 13 ◽  
Author(s):  
Blythe Adamson ◽  
Josh Carlson ◽  
James Kublin ◽  
Louis Garrison
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
The United States ◽  
Hiv Vaccines ◽  
Potential Cost ◽  
Exposure Prophylaxis

scholarly journals Potential Cost-Effectiveness of Pre-exposure Prophylaxis Combined with HIV Vaccines in the United States

2017 ◽  
Author(s):  
Blythe J.S. Adamson ◽  
Josh J. Carlson ◽  
James G. Kublin ◽  
Louis P. Garrison, Jr.
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Cost Effective ◽  
The United States ◽  
Hiv Vaccine ◽  
Base Case ◽  
Hiv Vaccines ◽  
Potential Cost ◽  
Lifetime Horizon ◽  
Exposure Prophylaxis

This economic evaluation aims to support policy-making on the combined use of pre-exposure prophylaxis (PrEP) with HIV vaccines by evaluating the potential cost-effectiveness of implementation that would support the design of clinical trials for assessment of combined product safety and efficacy. The target study population is a cohort of men who have sex with men (MSM) in the United States. Policy strategies considered include standard HIV prevention, daily oral PrEP, HIV vaccine, and their combination. We constructed a Markov model based on clinical trial data and published literature. We used a payer perspective, monthly cycle length, a lifetime horizon, and a 3% discount rate. We assumed a price of $500 per HIV vaccine series in the base case. HIV vaccines dominated standard care and PrEP. At current prices,PrEP was not cost-effective alone or in combination. A combination strategy had the greatest health benefit but was not cost-effective (ICER=$463,448/QALY) as compared to vaccination alone. Sensitivity analyses suggest a combination may be valuable for higher-risk men with good adherence. Vaccine durability and PrEP drug prices were key drivers of cost-effectiveness. Results suggest that boosting potential may be key to HIV vaccine value.

Cost-effectiveness of dental implants: a utility analysis

1990 ◽  
Vol 54 (11) ◽  
pp. 688-689 ◽  
Author(s):  
J Jacobson ◽  
B Maxson ◽  
K Mays ◽  
J Peebles ◽  
C Kowalski
Keyword(s):  
Cost Effectiveness ◽  
Dental Implants ◽  
Utility Analysis
Sign in / Sign up

Export Citation Format

Share Document